Sign in3 stories
The company reported $7.1 million in nine-month LYMPHIR revenue and $17 million in cash, while citing early-stage data expanding the drug's potential use beyond cutaneous T-cell lymphoma.
SEC filing
The company said 44 institutions have ordered LYMPHIR since launch, with institutional vial orders up 31% sequentially and $7.1 million in nine-month revenue.
SEC filing
The oncology-focused company, majority owned by Citius Pharmaceuticals, named the higher education and legal executive an independent director effective August 10, 2026.
SEC filing